Skip to main content
Erschienen in: Der Nervenarzt 5/2014

01.05.2014 | Übersichten

Nalmefen

Eine neue pharmakotherapeutische Option bei Alkoholabhängigkeit

verfasst von: Prof. Dr. M. Soyka

Erschienen in: Der Nervenarzt | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Rückfälle sind auch nach längeren Psycho- und Soziotherapien bei Alkoholabhängigkeit immer noch häufig. Bisherige evidenzbasierte Pharmakotherapien beschränken sich auf die Gabe von Acamprosat und den Opioidantagonisten Naltrexon. Beide Therapien haben in Deutschland keine weite Verbreitung gefunden. Von der European Medicine Agency (EMA) ist jetzt einem weiteren Opioidantagonisten, Nalmefen, der ebenso wie Naltrexon ein Antagonist am µ-Opioid-Rezeptor sowie ein partieller Agonist am κ-Rezeptor ist, eine Zulassung erteilt worden. Die bislang durchgeführten präklinischen und klinischen Untersuchungen mit Nalmefen werden dargestellt. Interessant erscheint, dass Nalmefen in den zulassungsrelevanten Therapiestudien nicht zur Abstinenzunterstützung, sondern als „As-needed“-Medikation zur Trinkmengenreduktion eingesetzt wurde.
Literatur
1.
Zurück zum Zitat Anton RF, Oroszi G, O Malley S et al (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135–144PubMedCentralCrossRefPubMed Anton RF, Oroszi G, O Malley S et al (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135–144PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Anton RF, Pettinati H, Zweben A et al (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24:421–428CrossRefPubMed Anton RF, Pettinati H, Zweben A et al (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24:421–428CrossRefPubMed
3.
Zurück zum Zitat Arias AJ, Armeli S, Gelernter J et al (2008) Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 32:1159–1166PubMedCentralCrossRefPubMed Arias AJ, Armeli S, Gelernter J et al (2008) Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 32:1159–1166PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Barson JC, Carr AJ, Soun JE et al (2010) Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake. Alcohol Clin Exp Res 34:214–222CrossRefPubMed Barson JC, Carr AJ, Soun JE et al (2010) Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake. Alcohol Clin Exp Res 34:214–222CrossRefPubMed
5.
Zurück zum Zitat Bart G, Schluger JH, Borg L et al (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30:2254–2262CrossRefPubMed Bart G, Schluger JH, Borg L et al (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30:2254–2262CrossRefPubMed
6.
Zurück zum Zitat Bazov I, Kononenko O, Watanabe H et al (2013) The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction. Addict Biol 18:161–169CrossRefPubMed Bazov I, Kononenko O, Watanabe H et al (2013) The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction. Addict Biol 18:161–169CrossRefPubMed
7.
Zurück zum Zitat Benerif B, Wand GS, McCaul ME et al (2004) Mu-opioid receptor binding measured by [11]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55:255–262CrossRef Benerif B, Wand GS, McCaul ME et al (2004) Mu-opioid receptor binding measured by [11]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55:255–262CrossRef
8.
Zurück zum Zitat Berglund M, Thelander S, Jonsson E (2003) Treating alcohol and drug abuse. An evidence based review. Wiley-VCH, Weinheim Berglund M, Thelander S, Jonsson E (2003) Treating alcohol and drug abuse. An evidence based review. Wiley-VCH, Weinheim
9.
Zurück zum Zitat Björk K, Terasmaa A, Sun H et al (2010) Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors. Addict Biol 15:299–303PubMedCentralCrossRefPubMed Björk K, Terasmaa A, Sun H et al (2010) Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors. Addict Biol 15:299–303PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Ciccocioppo R, Martin-Fardon R, Weiss F (2002) Effect of selective blockade of mu or delta opioid receptors on reinstatement of alcohol-seeking behavoir by drug-associated stimuli in rats. Neuropsychoharmacology 27:391–399CrossRef Ciccocioppo R, Martin-Fardon R, Weiss F (2002) Effect of selective blockade of mu or delta opioid receptors on reinstatement of alcohol-seeking behavoir by drug-associated stimuli in rats. Neuropsychoharmacology 27:391–399CrossRef
11.
Zurück zum Zitat Cowen MS, Lawrence AJ (1999) The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 23:1171–1212CrossRefPubMed Cowen MS, Lawrence AJ (1999) The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry 23:1171–1212CrossRefPubMed
12.
Zurück zum Zitat D’Addario C, Caputi FF, Rimondini R et al (2013) Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related to genes in rat brain. Addict Biol 18(3):425–433 CrossRef D’Addario C, Caputi FF, Rimondini R et al (2013) Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related to genes in rat brain. Addict Biol 18(3):425–433 CrossRef
13.
Zurück zum Zitat DeHaven-Hudkins DL, Brostrom PA, Allen JT et al (1990) Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37:497–504CrossRefPubMed DeHaven-Hudkins DL, Brostrom PA, Allen JT et al (1990) Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37:497–504CrossRefPubMed
14.
Zurück zum Zitat Dixon R, Gentile J, Hsu HB et al (1987) Nalmefene: safety and kinetics after single and multiple oral doses of a new antagonist. J Clin Pharmacol 27:233–239CrossRefPubMed Dixon R, Gentile J, Hsu HB et al (1987) Nalmefene: safety and kinetics after single and multiple oral doses of a new antagonist. J Clin Pharmacol 27:233–239CrossRefPubMed
15.
Zurück zum Zitat Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362–1370CrossRefPubMed Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362–1370CrossRefPubMed
16.
Zurück zum Zitat Emerson PJ, Lui MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630–1637 Emerson PJ, Lui MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630–1637
17.
Zurück zum Zitat Gal TJ, DiFazio CA, Dixon R (1986) Prolonged blockade of opioid with oral nalmefene. Clin Pharmacol Ther 40:537–542CrossRefPubMed Gal TJ, DiFazio CA, Dixon R (1986) Prolonged blockade of opioid with oral nalmefene. Clin Pharmacol Ther 40:537–542CrossRefPubMed
18.
Zurück zum Zitat Gianoulakis C (2004) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4:39–50CrossRefPubMed Gianoulakis C (2004) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4:39–50CrossRefPubMed
19.
Zurück zum Zitat Grant BF, Stinson FS, Dawson DA et al (2004) Results from the National Epidemiological Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:361–368CrossRefPubMed Grant BF, Stinson FS, Dawson DA et al (2004) Results from the National Epidemiological Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:361–368CrossRefPubMed
20.
Zurück zum Zitat Gual A, He Y, Torup L et al (2013) A randomized, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol DOI:pii:S0924–977+(13)00075-8 Gual A, He Y, Torup L et al (2013) A randomized, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol DOI:pii:S0924–977+(13)00075-8
21.
Zurück zum Zitat Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855–876CrossRefPubMed Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855–876CrossRefPubMed
22.
Zurück zum Zitat Heinz A, Reimold M, Wrase J et al (2005) Correlation of stable elevations in strital mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:57–64CrossRefPubMed Heinz A, Reimold M, Wrase J et al (2005) Correlation of stable elevations in strital mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:57–64CrossRefPubMed
23.
Zurück zum Zitat Herz A (1997) Endogenous opioid system and alcohol addiction. Psychopharmacology 129:99–111CrossRefPubMed Herz A (1997) Endogenous opioid system and alcohol addiction. Psychopharmacology 129:99–111CrossRefPubMed
24.
Zurück zum Zitat Ingman K, Hagelberg N, Aalto S et al (2005) Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30:2245–2253CrossRefPubMed Ingman K, Hagelberg N, Aalto S et al (2005) Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30:2245–2253CrossRefPubMed
25.
Zurück zum Zitat June HL, Cummings R, Eiler WJ II et al (2004) Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharinre inforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology 29:285–299CrossRefPubMed June HL, Cummings R, Eiler WJ II et al (2004) Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharinre inforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology 29:285–299CrossRefPubMed
26.
Zurück zum Zitat June HL, Grey C, Warren-Reese C et al (1998) The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 22:2174–2185PubMed June HL, Grey C, Warren-Reese C et al (1998) The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res 22:2174–2185PubMed
27.
Zurück zum Zitat Karhuvaara S, Simojoki K, Virta A et al (2007) Targeted nalmefene with simple medical management in the treatment oh heavy drinkers: a randomized double-blind placebo-controlled multicentre study. Alcohol Clin Exp Res 31:1179–1187CrossRefPubMed Karhuvaara S, Simojoki K, Virta A et al (2007) Targeted nalmefene with simple medical management in the treatment oh heavy drinkers: a randomized double-blind placebo-controlled multicentre study. Alcohol Clin Exp Res 31:1179–1187CrossRefPubMed
28.
Zurück zum Zitat Kessler RC, Chiu WT, Demler O et al (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627PubMedCentralCrossRefPubMed Kessler RC, Chiu WT, Demler O et al (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Kim S, Wagner HN Jr, Villemagne VL et al (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual detector system. J Nucl Med 38:1726–1731PubMed Kim S, Wagner HN Jr, Villemagne VL et al (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual detector system. J Nucl Med 38:1726–1731PubMed
30.
Zurück zum Zitat Kim SG, Kim CM, Jae YM et al (2009) A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 201:611–618 Kim SG, Kim CM, Jae YM et al (2009) A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 201:611–618
31.
Zurück zum Zitat Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177–184CrossRefPubMed Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177–184CrossRefPubMed
32.
Zurück zum Zitat Maisel NC, Blodgett JC, Wilbourne PL et al (2012) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108:275–293PubMedCentralCrossRefPubMed Maisel NC, Blodgett JC, Wilbourne PL et al (2012) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108:275–293PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Mann K, Bladström A, Torup L et al (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry DOI:10.1016/j.BIOPSYCH.2012.10.020 Mann K, Bladström A, Torup L et al (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry DOI:10.1016/j.BIOPSYCH.2012.10.020
34.
Zurück zum Zitat Mann K, Lemenager T, Hoffmann S et al (2012) Results of adouble-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. DOI:10.1111/adb.12012 Mann K, Lemenager T, Hoffmann S et al (2012) Results of adouble-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. DOI:10.1111/adb.12012
35.
Zurück zum Zitat Mason BJ, Ritvo EC, Morgan RO et al (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety nalmefene HCI for alcohol dependence. Alcohol Clin Exp Res 18:1162–1167CrossRefPubMed Mason BJ, Ritvo EC, Morgan RO et al (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety nalmefene HCI for alcohol dependence. Alcohol Clin Exp Res 18:1162–1167CrossRefPubMed
36.
Zurück zum Zitat Mason BJ, Salvato FR, Williams LD et al (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719–724CrossRefPubMed Mason BJ, Salvato FR, Williams LD et al (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719–724CrossRefPubMed
37.
Zurück zum Zitat Matz J, Graff C, Vainio PJ et al (2011) Effect of nalmefene 20 and 80 mg on the corrected QT-interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clin Drug Investig 31:799–811CrossRefPubMed Matz J, Graff C, Vainio PJ et al (2011) Effect of nalmefene 20 and 80 mg on the corrected QT-interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clin Drug Investig 31:799–811CrossRefPubMed
38.
Zurück zum Zitat Nealey KA, Smith AW, Davis SM et al (2011) K-opioid receptors are implicated in the inceased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neupharmacology 61:35–43CrossRef Nealey KA, Smith AW, Davis SM et al (2011) K-opioid receptors are implicated in the inceased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neupharmacology 61:35–43CrossRef
39.
Zurück zum Zitat Oroszi G, Anton RF, O Malley S et al (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383–393PubMedCentralCrossRefPubMed Oroszi G, Anton RF, O Malley S et al (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383–393PubMedCentralCrossRefPubMed
40.
42.
Zurück zum Zitat Pirkola SP, Poikolainen K, Lönnequist JK (2006) Currently active and remitted alcohol dependence in a nationwide adult general population – results from the Finnish health 2000 study. Alcohol Alcohol 41:321–327CrossRef Pirkola SP, Poikolainen K, Lönnequist JK (2006) Currently active and remitted alcohol dependence in a nationwide adult general population – results from the Finnish health 2000 study. Alcohol Alcohol 41:321–327CrossRef
43.
Zurück zum Zitat Rehm J, Room R, Brink W van den, Jacobi F (2005) Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol 15:377–388CrossRefPubMed Rehm J, Room R, Brink W van den, Jacobi F (2005) Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol 15:377–388CrossRefPubMed
44.
Zurück zum Zitat Rösner S, Hackl-Herrwerth A, Leucht S et al (2010) Acamprosate for alcohol dependence. Cochrane Database Syst Rev 9:CD004332PubMed Rösner S, Hackl-Herrwerth A, Leucht S et al (2010) Acamprosate for alcohol dependence. Cochrane Database Syst Rev 9:CD004332PubMed
45.
Zurück zum Zitat Rösner S, Hackl-Herrwerth A, Leucht S et al (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12:CD001867PubMed Rösner S, Hackl-Herrwerth A, Leucht S et al (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12:CD001867PubMed
46.
Zurück zum Zitat Soyka M, Kranzler HR, Berglund M et al (2008) World Federation of Societies of biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry 9:6–23CrossRefPubMed Soyka M, Kranzler HR, Berglund M et al (2008) World Federation of Societies of biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry 9:6–23CrossRefPubMed
47.
Zurück zum Zitat Soyka M (2013) Update Alkoholabhängigkeit. Unimed, Bremen Soyka M (2013) Update Alkoholabhängigkeit. Unimed, Bremen
48.
Zurück zum Zitat Spanagel R (2009) Alcoholism: a systems approach from the molecular physiology to addictive behavior. Physiol Rev 89:649–705CrossRefPubMed Spanagel R (2009) Alcoholism: a systems approach from the molecular physiology to addictive behavior. Physiol Rev 89:649–705CrossRefPubMed
49.
Zurück zum Zitat Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29:109–115CrossRefPubMed Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29:109–115CrossRefPubMed
50.
Zurück zum Zitat Spanagel R, Vengeliene V (2013) New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 13:583–609CrossRefPubMed Spanagel R, Vengeliene V (2013) New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 13:583–609CrossRefPubMed
51.
Zurück zum Zitat Vengeliene V, Celerier E, Chaskiel L et al (2009) Compulsive alcohol drinking in rodents. Addict Biol 14:384–396CrossRefPubMed Vengeliene V, Celerier E, Chaskiel L et al (2009) Compulsive alcohol drinking in rodents. Addict Biol 14:384–396CrossRefPubMed
52.
Zurück zum Zitat Volpicelli JR, Watson NT, King AC et al (1995) Effect of naltrexone on alcohol ‚high‘ in alcoholics. Am J Psychiatry 152:613–615PubMed Volpicelli JR, Watson NT, King AC et al (1995) Effect of naltrexone on alcohol ‚high‘ in alcoholics. Am J Psychiatry 152:613–615PubMed
53.
Zurück zum Zitat Walker BM, Koob GF (2008) Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33:643–652PubMedCentralCrossRefPubMed Walker BM, Koob GF (2008) Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33:643–652PubMedCentralCrossRefPubMed
54.
Zurück zum Zitat Walker BM, Zorilla EP, Koob GF (2011) Systematic k-opioid receptor antagonism by norbinaltorphimine reduces rependence-induced exzessive alcohol self-administration in rats. Addict Biol 16:116–119PubMedCentralCrossRefPubMed Walker BM, Zorilla EP, Koob GF (2011) Systematic k-opioid receptor antagonism by norbinaltorphimine reduces rependence-induced exzessive alcohol self-administration in rats. Addict Biol 16:116–119PubMedCentralCrossRefPubMed
55.
Zurück zum Zitat Walker BM, Valdez GR, McLaughlin JP, Bakalkin G (2012) Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol 46:359–370PubMedCentralCrossRefPubMed Walker BM, Valdez GR, McLaughlin JP, Bakalkin G (2012) Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol 46:359–370PubMedCentralCrossRefPubMed
56.
Zurück zum Zitat Wee S, Koob GF (2010) The role of the dynorphin-kappa opioid receptor system in the reinforcing effects of drugs of abuse. Psychopharmacology 210:121–135PubMedCentralCrossRefPubMed Wee S, Koob GF (2010) The role of the dynorphin-kappa opioid receptor system in the reinforcing effects of drugs of abuse. Psychopharmacology 210:121–135PubMedCentralCrossRefPubMed
57.
Zurück zum Zitat Weerts EM, Wand GS, Kuwabara H et al (2011) Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res 35:2162–2173PubMedCentralCrossRefPubMed Weerts EM, Wand GS, Kuwabara H et al (2011) Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res 35:2162–2173PubMedCentralCrossRefPubMed
58.
Zurück zum Zitat Williams TM, Davies SJ, Tylor LG et al (2009) Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an (11C) diprenorphine PT study. Eur Neuropsychopharmacol 19:740–748CrossRefPubMed Williams TM, Davies SJ, Tylor LG et al (2009) Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an (11C) diprenorphine PT study. Eur Neuropsychopharmacol 19:740–748CrossRefPubMed
59.
Zurück zum Zitat Davies DL, Bortolato M, Finn DA et al. (2013) Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res 37:8–15PubMedCentralCrossRefPubMed Davies DL, Bortolato M, Finn DA et al. (2013) Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res 37:8–15PubMedCentralCrossRefPubMed
Metadaten
Titel
Nalmefen
Eine neue pharmakotherapeutische Option bei Alkoholabhängigkeit
verfasst von
Prof. Dr. M. Soyka
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Der Nervenarzt / Ausgabe 5/2014
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-013-3843-3

Weitere Artikel der Ausgabe 5/2014

Der Nervenarzt 5/2014 Zur Ausgabe

Mitteilungen der DGPPN

Mitteilungen der DGPPN 5/2014